Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

31 results
Display

Combined Use of the Modified Hodge Test and Carbapenemase Inhibition Test for Detection of Carbapenemase-Producing Enterobacteriaceae and Metallo-beta-Lactamase-Producing Pseudomonas spp.

Song W, Hong SG, Yong D, Jeong SH, Kim HS, Kim HS, Kim JS, Bae IK

BACKGROUND: We evaluated the combined use of the modified Hodge test (MHT) and carbapenemase inhibition test (CIT) using phenylboronic acid (PBA) and EDTA to detect carbapenemase-producing Enterobacteriaceae (CPE) and metallo-beta-lactamase...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation

Lee J, Kim BS, Park Y, Lee JG, Lim BJ, Jeong HJ, Kim YS, Huh KH

PURPOSE: Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Bortezomib on Expression of Inflammatory Cytokines and Survival in a Murine Sepsis Model Induced by Cecal Ligation and Puncture

Han SH, Kim JS, Woo JH, Jeong SJ, Shin JS, Ahn YS, Kim JM

PURPOSE: Although the proteasome inhibitor known as bortezomib can modulate the inflammatory process through the nuclear factor-kappa B signaling pathway, the immunomodulatory effect of pre-incubated bortezomib has not been fully...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of Bortezomib as Anti-Humoral Therapy in Kidney Transplantation

Yang KS, Jeon H, Park Y, Jo IH, Kim JI, Moon IS, Choi BS, Park CW, Yang CW, Kim YS, Chung BH

This study aimed to investigate the effect of bortezomib in the desensitization and treatment of acute antibody mediated rejection (AAMR) in kidney transplantation. Nine patients who received bortezomib therapy for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma

Min CK, Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG, Kim DW, Lee JW, Min WS, Park CW

BACKGROUND: Novel agents (NAs) such as thalidomide and bortezomib have been administered in combination with autologous stem-cell transplantation (ASCT) to effectively treat multiple myeloma (MM). However, whether NAs perform better...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Primary Systemic Amyloidosis Confirmed by Various Diagnostic Tools and Repeated Skin Biopsies

Ko BJ, Lee GM, Choi IH, Park YL, Lee SY, Whang KU

  • KMID: 2246593
  • Korean J Dermatol.
  • 2013 Sep;51(9):713-717.
Amyloidosis is a group of disorders resulting from the extracellular deposition of amyloid fibrils in tissues and organs. Primary systemic amyloidosis may be myeloma-associated or idiopathic. It involves the kidney,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bortezomib Reduces Neointimal Hyperplasia in a Rat Carotid Artery Injury Model

Kim KS, Kim SY, Choi JH, Joo SJ, Kim DW, Cho MC

BACKGROUND AND OBJECTIVES: The ubiquitin-proteasome system is the major intracellular protein degradation pathway in the eukaryotic cells. Bortezomib inhibits 26S proteasome-induced I-kappaBalpha degradation and suppresses nuclear factor-kappa B (NF-kappaB) activation....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bortezomib Induced Tumor Lysis Syndrome in Multiple Myeloma

Yu S, Ryu SW, Kim KH, Kim SH, Lee NS, Park SK, Won JH

  • KMID: 2317696
  • Soonchunhyang Med Sci.
  • 2013 Jun;19(1):31-33.
The tumor lysis syndrome (TLS) commonly occurs in the lymphoproliferative disorder, either spontaneously or in response to therapy. TLS is uncommon in multiple myeloma. However, with the use of bortezomib...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diagnosis and therapy of multiple myeloma

Palumbo A, Cerrato C

Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel agents including thalidomide, lenalidomide, and bortezomib. The first...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma

Ahn JS, Rew SY, Yang DH, Jung SH, Kang SJ, Kim MY, Lee SS, Kim YK, Kim HJ, Lee JJ

BACKGROUND: Bortezomib administration leads to a transient decrease in CD4+ T cells, increasing the susceptibility to opportunistic infections. The activation and proliferation of CD4+ T cells are particularly important in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells

Song IS, Jeong YJ, Jeong SH, Heo HJ, Kim HK, Lee SR, Ko TH, Youm JB, Kim N, Ko KS, Rhee BD, Han J

  • KMID: 2154269
  • Exp Mol Med.
  • 2013 Oct;45(10):e50.
Bortezomib is a proteasome inhibitor used for the treatment of relapsed/refractory multiple myeloma (MM). However, intrinsic and acquired resistance to bortezomib has already been observed in MM patients. In a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation

Lee HS, Kim YS, Kim K, Kim JS, Kim HJ, Min CK, Suh C, Eom HS, Yoon SS, Lee JH, Kim MK, Kim SH, Bae SH, Mun YC, Jo DY, Chung JS, The Korean Multiple Myeloma Working Party (KMMWP)

Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma

Kim Y, Kim KY, Lee SH, Chung YY, Yahng SA, Lee SE, Park G, Min CK

We report on a case of severe hepatotoxicity in a 52-year-old male with multiple myeloma (MM) who had received bortezomib therapy. At patient presentation, liver enzymes were normal, but started...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas

Kim JE, Yoon DH, Jang G, Lee DH, Kim S, Park CS, Huh J, Kim WS, Park J, Lee JH, Lee SI, Suh C

BACKGROUND: Bortezomib targets molecular dysregulation of nuclear factor-kappaB activation and cell cycle control, which are characteristic features of diffuse large B-cell lymphoma (DLBCL). We evaluated the safety and efficacy of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Multiple Solitary Plasmacytoma Recurring in Multiple Visceral Organs

Song IC, Baek SW, Lee KS, Yun GW, Yang YJ, Kim JM, Jo DY

  • KMID: 2258964
  • Korean J Med.
  • 2011 May;80(5):609-614.
Multiple solitary plasmacytoma is a very rare disease entity, which occurs in up to 5% of patients with solitary plasmacytomas. We report an atypical case of multiple solitary plasmacytoma that...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Proteasome-Inhibitor-Based Primary Therapy for Antibody-Mediated Rejection in a Renal Transplant Recipient

Park SJ, Yu H, Kang SH, Baek SD, Baek CH, Jeong JH, Park SK

  • KMID: 2264162
  • Korean J Med.
  • 2011 Dec;81(6):780-785.
Donor-specific anti-human leukocyte antigen antibodies (DSA) following kidney transplantation predict the evolution of humoral rejection and reduced graft survival. Rapid, complete elimination of DSA during antibody-mediated rejection (AMR) is rarely...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Escherichia coli pap Genes as well as Adenovirus Type 11 and Type 21, and BK Virus were Involved with Severe Urinary Tract Infection in Infants

Park HK, Woo SY, Lee EO, Cha JE, Lee KE, Park H, Lee SJ

In infants, urinary tract infections (UTIs) are quite common and primarily caused by bacterial pathogens. However, little research has been conducted regarding the relationship between uropathogenic bacteria, virulent genes, and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma

Lee WS, Kim DH, Shin SH, Woo SI, Kwan J, Park KS, Park SD, Yi HG, Jeon SH

Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy. Here...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Maintaining the Constant Exposure Condition for an Acute Caenorhabditis elegans Mortality Test Using Passive Dosing

Kwon HC, Roh JY, Lim D, Choi J, Kwon JH

  • KMID: 2380165
  • Environ Health Toxicol.
  • 2011 ;26(1):e2011015.
OBJECTIVES: Maintaining the constant exposure to hydrophobic organic compouds in acute toxicity tests is one of the most difficult issues in the evaluation of their toxicity and corresponding risks. Passive...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma

Yi YS, Chung JS, Song MK, Shin HJ, Seol YM, Choi YJ, Cho GJ, Lee GW, Moon JH, Hwang IH, Ahn KH, Lee HS, Shin KH, Hwang JM

BACKGROUND: Bortezomib has significant activity in treating multiple myeloma (MM). The risk of herpes zoster (HZ) has been reported to increase significantly with bortezomib treatment, but the predisposing factors for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr